Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 150.85
ARWR's Cash to Debt is ranked higher than
75% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. ARWR: 150.85 )
ARWR' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 150.85

Equity to Asset 0.91
ARWR's Equity to Asset is ranked higher than
92% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ARWR: 0.91 )
ARWR' s 10-Year Equity to Asset Range
Min: -32.54   Max: 0.91
Current: 0.91

-32.54
0.91
F-Score: 4
Z-Score: 12.73
M-Score: -4.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -30269.89
ARWR's Operating margin (%) is ranked lower than
51% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. ARWR: -30269.89 )
ARWR' s 10-Year Operating margin (%) Range
Min: -70800   Max: -40
Current: -30269.89

-70800
-40
Net-margin (%) -33312.50
ARWR's Net-margin (%) is ranked lower than
51% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. ARWR: -33312.50 )
ARWR' s 10-Year Net-margin (%) Range
Min: -33502.86   Max: 1602.7
Current: -33312.5

-33502.86
1602.7
ROE (%) -44.79
ARWR's ROE (%) is ranked higher than
71% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. ARWR: -44.79 )
ARWR' s 10-Year ROE (%) Range
Min: -225.02   Max: -28.66
Current: -44.79

-225.02
-28.66
ROA (%) -41.17
ARWR's ROA (%) is ranked higher than
68% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. ARWR: -41.17 )
ARWR' s 10-Year ROA (%) Range
Min: -447.27   Max: 705.95
Current: -41.17

-447.27
705.95
ROC (Joel Greenblatt) (%) -1519.02
ARWR's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. ARWR: -1519.02 )
ARWR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11843.37   Max: -75
Current: -1519.02

-11843.37
-75
Revenue Growth (3Y)(%) -100.00
ARWR's Revenue Growth (3Y)(%) is ranked higher than
55% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. ARWR: -100.00 )
ARWR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 63.5
Current: -100

0
63.5
EBITDA Growth (3Y)(%) -5.80
ARWR's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. ARWR: -5.80 )
ARWR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -56.3   Max: 190.5
Current: -5.8

-56.3
190.5
EPS Growth (3Y)(%) 1.90
ARWR's EPS Growth (3Y)(%) is ranked higher than
81% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. ARWR: 1.90 )
ARWR' s 10-Year EPS Growth (3Y)(%) Range
Min: -75.1   Max: 162.1
Current: 1.9

-75.1
162.1
» ARWR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ARWR Guru Trades in

Q4 2013

ARWR Guru Trades in Q4 2013

Jim Simons 54,400 sh (New)
Steven Cohen 1,500,000 sh (New)
» More
Q1 2014

ARWR Guru Trades in Q1 2014

George Soros 44,200 sh (New)
Steven Cohen 2,740,000 sh (+82.67%)
Jim Simons Sold Out
» More
Q2 2014

ARWR Guru Trades in Q2 2014

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARWR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out 0.01%$9.79 - $18.28 $ 7.51-43%0
George Soros 2014-03-31 New Buy0.01%$9.92 - $26.57 $ 7.51-57%44200
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.30
ARWR's P/B is ranked higher than
87% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. ARWR: 2.30 )
ARWR' s 10-Year P/B Range
Min: 1.43   Max: 75.56
Current: 2.3

1.43
75.56
EV-to-EBIT -3.30
ARWR's EV-to-EBIT is ranked higher than
78% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARWR: -3.30 )
ARWR' s 10-Year EV-to-EBIT Range
Min: -71.7   Max: -0.3
Current: -3.3

-71.7
-0.3
Current Ratio 13.07
ARWR's Current Ratio is ranked higher than
89% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. ARWR: 13.07 )
ARWR' s 10-Year Current Ratio Range
Min: 0.01   Max: 22.28
Current: 13.07

0.01
22.28
Quick Ratio 13.07
ARWR's Quick Ratio is ranked higher than
90% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. ARWR: 13.07 )
ARWR' s 10-Year Quick Ratio Range
Min: 0.01   Max: 22.28
Current: 13.07

0.01
22.28

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.00
ARWR's Price/Net Cash is ranked higher than
93% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. ARWR: 3.00 )
ARWR' s 10-Year Price/Net Cash Range
Min: 0.05   Max: 21.43
Current: 3

0.05
21.43
Price/Net Current Asset Value 3.00
ARWR's Price/Net Current Asset Value is ranked higher than
93% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. ARWR: 3.00 )
ARWR' s 10-Year Price/Net Current Asset Value Range
Min: 0.05   Max: 21
Current: 3

0.05
21
Price/Tangible Book 2.50
ARWR's Price/Tangible Book is ranked higher than
90% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. ARWR: 2.50 )
ARWR' s 10-Year Price/Tangible Book Range
Min: 0.04   Max: 54.5
Current: 2.5

0.04
54.5
Price/DCF (Projected) 250.30
ARWR's Price/DCF (Projected) is ranked higher than
69% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARWR: 250.30 )
ARWR' s 10-Year Price/DCF (Projected) Range
Min: 166.11   Max: 492.33
Current: 250.3

166.11
492.33
Earnings Yield (Greenblatt) -29.20
ARWR's Earnings Yield (Greenblatt) is ranked higher than
55% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ARWR: -29.20 )
ARWR' s 10-Year Earnings Yield (Greenblatt) Range
Min: -32.1   Max: 0
Current: -29.2

-32.1
0

Analyst Estimate

Sep15 Sep16
Revenue(Mil) 0 11
EPS($) -1.48 -1.52
EPS without NRI($) -1.48 -1.52

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HDP1.Germany,
Arrowhead Research Corp was originally incorporated in South Dakota in 1989, and was reincorporated in Delaware in 2000. It is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Its pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. The product include ARC-520, Adipotide, CRLX-101, Tubulin Inhibitor.The drug products are regulated by FDA under the Federal Food, Drug and Cosmetic Act (the "FDCA"), and other laws within the Public Health Service Act.
» More Articles for ARWR

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
Arrowhead Reports Third Quarter Fiscal 2009 Financial Results Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
Arrowhead to Present at 2015 Barclays Global Healthcare Conference Mar 04 2015
Lightning Round: This is back in renaissance mode Feb 26 2015
Arrowhead Begins Phase 1 Trial of ARC-AAT for Treatment of Liver Disease Associated with Alpha-1... Feb 23 2015
Arrowhead to Present at 2015 RBC Capital Markets' Global Healthcare Conference Feb 17 2015
4 Biotech Stocks Under $10 to Trade for Breakouts: Sophiris, Atossa and More Feb 17 2015
ARROWHEAD RESEARCH CORP Financials Feb 14 2015
10-Q for Arrowhead Research Corp. Feb 11 2015
ARWR: Arrowhead Reports Fiscal 1Q15 Financial Results Feb 11 2015
The News That Should Move Arrowhead Research Today Feb 10 2015
Arrowhead Research Corp Earnings Call scheduled for 4:30 pm ET today Feb 09 2015
Arrowhead Research reports 1Q loss Feb 09 2015
Arrowhead Research reports 1Q loss Feb 09 2015
ARROWHEAD RESEARCH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 09 2015
Arrowhead Reports Fiscal 2015 First Quarter Financial Results Feb 09 2015
Q1 2015 Arrowhead Research Corp Earnings Release - After Market Close Feb 09 2015
Arrowhead to Report Fiscal 2015 First Quarter Financial Results Feb 02 2015
Arrowhead Research Corp (ARWR): Bridger Management Builds 5.5% Passive Stake Jan 26 2015
Robbins Arroyo LLP Is Investigating the Officers and Directors of Arrowhead Research Corporation... Jan 14 2015
Arrowhead Research (ARWR) Stock Plummets Today After FDA Partial Clinical Hold Jan 12 2015
Arrowhead Research Tumbles 20% Following FDA News Jan 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK